Metformin as a potential neuroprotective agent that influence Parkinson's disease.

Parkinson's disease (PD) is a significant neurodegenerative complication that impacts around 2% of individuals over the age of 65. The disease is characterized by a gradual decline of nigrostriatal dopaminergic neurons, which leads to physical impairments in individuals. Unfortunately, no drugs are currently available that can halt the progression and alleviate the symptoms of PD. Recently, there has been growing evidence to suggest a link between PD and type-2 diabetes (T2DM) which may provide a pharmacological explanation for this relation. In this review, we examine the literature that supports the pathological changes of Parkinson's disease, overlap of PD with diabetes mellitus, the neuro-protective mechanism of metformin including autophagy activation, α-synuclein build-up, inhibition of activity of mitochondrial complex I and anti-inflammatory action. We also explore the data of epidemiological investigations of metformin therapy in diabetic patients, exploring its potential benefits against age-related neuro-degeneration in both animal models and humans. Despite some conflicting results from animal and clinical research, we believe that the evidence suggests a potential role for metformin as a treatment for neuronal disorders, and further research is needed to establish this. In conclusion, our review provides insights into the connections between PD and T2DM, and suggests that metformin could be an effective therapy for neurodegenerative conditions.